MAINZ BIOMED N.V. Completes $2.15M ATM Offering, Selling 1.7M Shares
Summary
Mainz Biomed N.V. announced the completion of a $2.15 million At-The-Market (ATM) offering, selling 1.7 million ordinary shares, which represents a significant capital raise relative to its market capitalization.
Key Events
-
Completes $2.15 Million ATM Offering
Mainz Biomed N.V. sold 1,735,194 ordinary shares between January 5 and January 23, 2026, generating gross proceeds of $2,152,822.40.
-
Significant Capital Infusion
The $2.15 million raised represents a substantial amount relative to the company's current market capitalization, providing critical funding for operations.
-
Remaining ATM Capacity
The specific prospectus supplement for $2.15 million has been fully utilized, but the company retains remaining capacity under its overall $10 million At-The-Market program for future sales.
Analysis
This 8-K filing details the successful completion of a $2.15 million At-The-Market (ATM) offering, which was initiated with a prospectus supplement on December 29, 2025. The company sold 1,735,194 ordinary shares between January 5 and January 23, 2026, generating gross proceeds of $2,152,822.40. For a company with a market capitalization of approximately $8.1 million, this represents a substantial capital infusion, providing crucial funding for operations. While highly dilutive, the successful execution of this offering is a positive signal for the company's near-term liquidity and ability to fund its ongoing product development in the life sciences sector. The company still has remaining capacity under its overall $10 million ATM program.
At the time of this filing, MYNZ was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $0.60 to $8.16. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.